H-11047: A Study of PS-341 Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate (Spore #: 11-01-30-13)

Trial Information

H-11047: A Study of PS-341 Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate (Spore #: 11-01-30-13)

In murine and human xenograft tumor models, administration of PS-341 weekly was associated
with significant antitumor activity. In primate studies using a schedule of twice weekly for
six weeks, the highest PS-341 dose not associated with severe irreversible toxicity was
0.067 mg/kg/dose or 0.80 mg/m2/dose. The PS-341 dose selected for this study, 1.6 mg/m2,
and the dose regimen of a 4-week treatment schedule (PS-341 once weekly for four weeks on
days 1, 8, 15 and 22) is supported by preclinical data and data collected in the completed
Phase I studies conducted in advanced solid tumors and hematologic malignancies. In the
Phase I dose escalation study conducted at the M.D. Anderson Cancer Center that is sponsored
by Millennium Pharmaceuticals, in patients with solid tumors in which PS-341 was
administered once per week for four weeks followed by a 14-day rest period (35-day cycle),
the observed MTD was 1.8 mg/m2.11,12 The LTs were observed at 2.0 mg/m2 and included
hypotension, diarrhea, and fatigue. Fifty-three patients were treated in this study and
received a maximum of 15 cycles. At the dose level 1.60 mg/m2, 70%-75% 20S proteasome
inhibition and peripheral blood was achieved at this dose. One false response, a major
radiographic response of retroperitoneal lymph nodes without PSA change was noted in a
prostate cancer patient and a second prostate patient had radiographic stabilization of a
retroperitoneal lymph node with an unchanged PSA. One partial response, a major
radiographic response of retroperitoneal lymph nodes without PSA change was noted in a
prostate cancer patient and a second prostate patient had radiographic stabilization of a
retroperitoneal lymph node with an unchanged PSA. One partial response, a major
radiographic response of retroperitoneal lymph nodes without PSA change was noted in a
prostate cancer patient and a second prostate patient had radiographic stabilization of a
retroperitoneal lymph node with an unchanged PSA. Further company-sponsored trial at
Memorial Sloan-Kettering Cancer Center is assessing twice weekly administration for two
weeks every three weeks. This trial is currently dosing at 1.65 mg/m2 and a proteasome
inhibition is in the range of 74-78%. One prostate cancer patient has had a significant
decrease in PSA levels. There have been no dose-limiting toxicities noted in either of the
studies to date, although drug associated toxicities have included fatigue, fever, nausea
and vomiting, anorexia, diarrhea and thrombocytopenia. The NCI is sponsoring three Phase I
trials of PS-341 administered IV twice weekly (days 1 and 4). One trial is assessing an
every other week administration of PS-341 in patients with solid tumors and non-Hodgkin's
lymphoma. A weekly times 4 every six weeks schedule is being evaluated in patients with
solid tumors and B cell lymphoproliferative disorders. A third trial is evaluating the same
administration schedule in patients with acute myeloid leukemias, myelodysplastic syndromes
and chronic myeloid leukemia in blast phase.14 These trials have all recently opened. Based
on these observations, PS-341 will be administered once a week for 4 weeks with a 24-72 hour
recovery period prior to radical prostatectomy.

We propose to study the in vivo effect of systemic treatment with PS-341 doing correlative
scientific markers assessing apoptosis, evaluation of protease protein targets, angiogenesis
markers. We do not anticipate any perioperative morbidity when prostatectomy is performed
24-72 hours following the last drug dose. A residual drug activity may impact transiently
on wound healing or on operative blood loss but this effect (if present) should dissipate
within a short period while proteasome activity recovers in all normal tissues. Long term
effects on the vesico-urethral anastomosis or the recovery of bladder and erectile functions
are not expected.

At the same time, obtaining the prostate within 72 hours (at most) following the last drug
dose should enable us to evaluate multiple protein markers while still influenced by
proteasome inhibition and to document biologic activity of the drug in the target organ.